10.1016/j.jaip.2022.01.038Pruritus can be a debilitating symptom for patients with
progressive familial intrahepatic cholestasis (PFIC), a disease that commonly presents
in young children. In the phase 3 PEDFIC 1 study (NCT03566238), odevixibat, an ileal
bile acid transporter inhibitor, reduced pruritus compared with placebo based on caregiver
report in children with PFIC using the PRUCISION scale. Patient-reported pruritus
data were also collected from patients aged ≥8 years. This analysis examines the correlation
between patient- and caregiver-reported pruritus scores in PEDFIC 1.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Value in HealthAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2022 Published by Elsevier Inc.
